DOCSLIB.ORG

Interactions Between Magnesium and Drugs in the Treatment of .Hypertension

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Interactions Between Magnesium and Drugs in the Treatment of .Hypertension Interactions between magnesium and drugs in the treatment of .hypertension W. P. Leary Zusammenfassung Summary Resume Der Herzmuskel kann ungi.instig durch The heart may be adversely affected by Les medicaments antihypertenseurs peu­ eine antihypertensive Medikation beein­ antihypertensive medications causing vent avoir un effet prejudiciable sur le fluBt werden, die Magnesium (Mg2+) magnesium (Mg2+) depletion or reduced creur en provoquant une depletion en -Verarmung verursacht oder den Influx inflow of the ion across the sarcolemma. magnesium (Mg++) ou une diminution dieses Ions durch das Sarcolemma redu­ Common diuretics cause hypermagnesi­ de !'influx de !'ion a travers le sarcolem­ ziert. Die iiblichen Diuretika fi.ihren zu uresis as may the angiotensin converting me. Les diuretiques usuels, de meme que Hypermagnesiurie, die auch durch den enzyme (ACE) inhibitor captopril. Some le captopril, un inhibiteur de !'enzyme de Hemmer von ACE (angiotensin conver­ calcium antagonists interfere with Mg2+. conversion de l'angiotensine, provoquent ting enzyme), das Gaptopril, verursacht entry to the myocardium. Single doses of une hypermagnesiurie. Certains inhibi­ werden kann. Einige Calcium-Antagoni­ various diuretics including clopamide teurs calciques interferent dans la pene­ tration de Mg++ dans sten interferieren mit der Mg2+-Aufnah­ 5 mg, chlorthalidone 100 mg, hydrochlo­ le myocarde. Des doses uniques de divers diuretiques - me ins Myocard. Die einmalige Gabe rothiazide 25, 50 mg, xipamide 5, 10, verschiedener Diuretika, eingeschlossen par exemple 5 mg de clopamide, I 00 mg 20 mg, and furosemide 40 mg significant­ de chlortalidone, 25 ou 50 mg d'hydro­ Clopamid 5 mg, Chlorthalidon 100 mg, ly increase 24 hour urinary excretion of Hydrochlorothiazid 25 und 50 mg, Xipa­ chlorothiazide, 5, I 0 ou 20 mg de xipami­ Mg2+. The loop diuretics muzolimine 30, de et 40 mg de furosemide- augmentent mid 5, 10 und 20 mg, und Furosemid 40 mg and torasemide 5, 10 mg and the 40 mg steigert signifikant die Mg2+.Aus­ significativement !'excretion urinaire de postassium-retaining diuretic amiloride 5, Mg+ + sur 24 heures. En revanche, 30 ou scheidung im 24-Stunden-Urin. Die 10 mg do not affect Mg2+ excretion ad­ Schleifendiuretika Muzolimin 30 und 40 mg de muzolimine et 5 ou I 0 mg de to­ versely. Mechanisms whereby common rasemide (diuretiques de l'anse), de meme 40 mg, und Torasemid 5 und l 0 mg sowie diuretics induce MgZ+ excretion are com­ das kaliumretinierende Diuretikum Ami­ que 5 ou 10 mg d'amiloride, un diureti­ plex and may involve" parathyroid hor­ que d'epargne potassique, n'ont pas d'ef­ lorid, 5 und 10 mg, haben keinen negati­ mone and the renin-angiotensin-aldo­ ven Effekt auf die Mg2:t-Ausscheidung. fet prejudicilible sur !'excretion de Mg+ +. sterone system. The beta blocker p,indol­ Les mecanismes Die Mechanismen, iiber die die iiblichen de I'hypermagnesiurie ol, amiloride and the ACE-inhibitor indiuite par les Diuretika die Mg2+-Exkretion induzie­ cap­ diuretiques courants sont topril' all reduce urinary complexes et peuv'ent impliquer la 'parat­ ren, sind komplex und kOnnen Parathor­ losses of Mg2+ which occur in response to acute doses of hormone et le systeme renine-angiotensi­ mon und das Renin-Angiotensin-Aldo­ ne-aldosterone. Le pindolol (beta-blo­ steron-System einschlieBen. Der Beta­ distal tubular diuretics. Some experimen­ tal evidence suggests that Mg2+ deficien­ quant), l'amiloride"et le captopril (un in­ blocker Pindolol, Amilorid und der hibiteur de l'enzyme, de conversion de ACE-Inhibitor Captopril mindern jeweils cy might contribute to the pathogenesis of essential hypertension. Studies in hy­ l'angiotensine) reduisent to us 1es fuites Mg2+-Verluste i.iber den Harn, die nach urinaires de Mg+ + induites par les doses akuter Gabe von Diuretika erfolgen, wel· pertensive patients do not provide con­ vincing support for this postulate. Mg2+ aigutls des diuretiques d'effet tubulaire che am distalen Tubulus angreifen. Eini­ distal. Certaines donnees experimentales ge experimentelle Oaten lassen vermuten, deficiency may he a coronary risk factor. Accordingly MgZ+ depletion should be plaident en faveur d'un role du deficit en daB Mg2+-Mangel an der Pathogenese Mg+ + dans la pathogenie de !'hyperten­ der essentiellen Hypertonie beteiligt ist. avoided during prolonged treatment of arterial hypertension. J'he clinical presen­ sion essentielle, mais les etudes menees Studien an Hochdruckpatienten stiitzen chez des malades hypertendus tation of MgZ+ deficiency is non-specific n'etayent diese Annahme aber nicht i.iberzeugend. pas cette hypothese de fayon convaincan­ but the condition Mg2+-Mangel kann einen koronaren Ri­ should be suspected te. Le deficit en Mg+ + peut constituer un sikofaktor beinhalten. Entsprechend soll­ whenever therapy with magnesiuretics facteur de risque coronarien. 11 faut done te eine Verarmung an MgZ+ wahrend der has been prolonged, particularly when prevenir un deficit en Mg+ + pendant le Langzeit-Behandlung der arteriellen Hy­ other factors favouring the development traitement au long cours de !'hyperten­ pertension vermieden werden. Das klini­ of Mg2+ deficiency are present. · sion arterielle. Le tableau clinique du de­ sche Bild des Mg2+-Mangels ist unspezi­ ficit en Mg++ n'est pas specifique, mais fisch; der Verdacht sollte aber immer be­ un tel deficit doit etre suspecte en cas de stehen bei Langzeit-Behandlung mit traitement prolonge par des medicaments MgZ+-ausscheidenden Diuretika und ins­ magnesiuretiques, surtout s'il existe en besondere dann, wenn andere Faktoren meme temps d'autres facteurs suscepti­ vorhanden ,sind, die die Entwicklung ei­ University of Natal, Durban/South Af­ bles de favoriser le developpement d'une nes Mg2+-Mangels begiinstigen. rica carence en magnesium. 62 . Mag.~Bull. 9 {1987) Interaetions 'betweell magnesium and drugs in .the treatment of hypertension The to le of magnesium (Mg2+) van der By!, K.;: unpublished)~ Diuretics in the three main in both the healthy and malfunc­ Some ca.z+ antagonists may also groups are not interchangeable in tioning cardiov·ascular system interfere with Mg~ + entry in the the management of hypertension has recently become the focus of myocardium [22, 23]. [69]. Loop diuretics do not con­ increasing research and interest form to the strict definition of [8, 20, 28, 29, 30, 39, 73, 79, 85, antihypertensive diuretics [76] 86, 94, 96, 98]. The magnesium Effects of diuretics on and should not be used as mono­ ion appears necessary for opti­ magnesium turnover therapy for uncomplicated hy­ mal regulation of electrical phen­ pertension; they are useful when omena at the sarcolemma and hypertension and renal insuffi­ also, in certain circumstances, for Diuretics and the treatment of ciency coexist, in treatment of the maintenance of an appro­ hypertension hypertensive crises and when the priately low tone in the coronary The diuretics most commonly coadministration of Na +-retain­ arterial musculature. Magnesium used at present are divisible into ing antihypertensives such as va­ deficiency may be complicated three groups in accordance with sodilators and some sympathetic by clinically important cardiac their principal sites of action blockers has caused a syndrome arrhythmias and has also been within the kidney. Loop diuretics of pseudo-resistant hypertension identified as an important risk such as furosemide, muzolimine, [76]. Early distal tubular diuret­ factor for cardiac ischaemic epi­ piretanide and bumetanide exer­ ics are widely employed as drugs sodes including myocardial in­ cise their main renal effect at a of ftrst-choice for the monother­ farction [3, 20, 28, 94]. Most of common site located in the thick apy of uncomplicated essential the adverse cardiovascular ef­ ascending segment'1of the loop of hypertension and their use in fects associated with Mg2+ defi­ Henle. Early distal tubular di­ combination with other antihy­ ciency may be accounted for by uretics, including the thiazides, pertensive substances is also ac­ the induction of significant intra­ chlorthalidone, clopamide, inda­ cepted practice in many coun­ cellular electrolyte imbalances pamide and xipamide, act at spe­ tries [50, I 00]. The K +-retaining including increases in cytosolic cific acceptors for each substance diuretics are not used as monoth­ Ca2+ and Na+ and a decrease in erapy but in the first portion of the distal are sometimes admin­ cytosolic K + [3, 39, 64, 95]. istered with convoluted tubule. The K +-re­ antihypertensive di­ The heart may be adversely af­ uretics in order to limit the taining diuretics spironolactone, sever­ fected by antihypertensive for­ ity of electrolyte imbalances as­ amiloride and triamterene act mulations which promote Mg2+ in sociated with the prolonged use the terminal depletion or reduce the inflow of part of the distal of these substances. the ion across the sarcolemma convoluted tubule where they in­ and the antihypertensive efficacy hibit transparietal exchange be­ Diuretics of these substances could also be tween Na +, which is normally and magnesium deple­ unfavourably affected by der­ reabsorbed from the pre-urine, tion anged Mg2+ turnover within vas­ and K+ and H+ which are ex­ Potassium deftciency secondary cular tissues. Common antihy­ creted fromthe milieu interieur. to increased urinary losses of the pertensive diuretics are known to In view of their widespread clini• ion has usually been identifted as augment urinary Mg2+ excretion cal use, loop and tubular diuret­ the most important cause of car­ and may
Load more

Recommended publications
  • Interactions Medicamenteuses Index Des Classes Pharmaco
    INTERACTIONS MEDICAMENTEUSES INDEX DES CLASSES PHARMACO-THERAPEUTIQUES Mise à jour avril 2006 acides biliaires (acide chenodesoxycholique, acide ursodesoxycholique) acidifiants urinaires adrénaline (voie bucco-dentaire ou sous-cutanée) (adrenaline alcalinisants urinaires (acetazolamide, sodium (bicarbonate de), trometamol) alcaloïdes de l'ergot de seigle dopaminergiques (bromocriptine, cabergoline, lisuride, pergolide) alcaloïdes de l'ergot de seigle vasoconstricteurs (dihydroergotamine, ergotamine, methylergometrine) alginates (acide alginique, sodium et de trolamine (alginate de)) alphabloquants à visée urologique (alfuzosine, doxazosine, prazosine, tamsulosine, terazosine) amidons et gélatines (gelatine, hydroxyethylamidon, polygeline) aminosides (amikacine, dibekacine, gentamicine, isepamicine, kanamycine, netilmicine, streptomycine, tobramycine) amprénavir (et, par extrapolation, fosamprénavir) (amprenavir, fosamprenavir) analgésiques morphiniques agonistes (alfentanil, codeine, dextromoramide, dextropropoxyphene, dihydrocodeine, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil, tramadol) analgésiques morphiniques de palier II (codeine, dextropropoxyphene, dihydrocodeine, tramadol) analgésiques morphiniques de palier III (alfentanil, dextromoramide, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil) analogues de la somatostatine (lanreotide, octreotide) androgènes (danazol, norethandrolone, testosterone) anesthésiques volatils halogénés
    [Show full text]
  • Summary of Product Characteristics
    Sandoz Business use only Page 1 of 9 1.3.1 spc-label-pl - common-spc – 11,006 20191218 (DE/H/1772/001-002-003 – 155347 - validation) TORASEMIDE 100 MG, 200 MG, 50 MG, TABLET 721-6534.01, 721-6535.01, 721-6536.01 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT [Nationally completed name] 50 mg tablets [Nationally completed name] 100 mg tablets [Nationally completed name] 200 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 50 mg of torasemide. Each tablet contains 100 mg of torasemide. Each tablet contains 200 mg of torasemide. For excipients, see section 6.1 3. PHARMACEUTICAL FORM Tablet. 50 mg tablets: White to off-white round tablet. 100 mg tablets: White to off-white round tablet with break notch. The tablet can be divided into equal doses. 200 mg tablets: White to off-white round tablet with cross break notch on both sides. The tablet can be divided into four equal doses. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications The administration of [Nationally completed name] 50 mg/- 100 mg/- 200 mg tablets is exclusively indicated in patients with highly reduced renal function (creatinine clearance less than 20 ml/min and/or serum creatinine concentration greater than 6 mg/dl). For maintenance of residual diuresis in case of severe renal insufficiency – even on dialysis if there is a considerable residual diuresis (more than 200 ml/24 hours) – if oedemas, effusions and/or hypertension exist. Note: [Nationally completed name] 50 mg/- 100 mg/- 200 mg tablets tablets are to be used only in case of highly impaired and not in normal renal function.
    [Show full text]
  • High-Throughput Screening Studies of Inhibition of Human Carbonic Anhydrase II and Bacterial Flagella Antimicrobial Activity
    Western Michigan University ScholarWorks at WMU Dissertations Graduate College 5-2010 High-Throughput Screening Studies of Inhibition of Human Carbonic Anhydrase II and Bacterial Flagella Antimicrobial Activity Albert A. Barrese III Western Michigan University Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Biochemistry, Biophysics, and Structural Biology Commons, and the Biology Commons Recommended Citation Barrese, Albert A. III, "High-Throughput Screening Studies of Inhibition of Human Carbonic Anhydrase II and Bacterial Flagella Antimicrobial Activity" (2010). Dissertations. 500. https://scholarworks.wmich.edu/dissertations/500 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. HIGH-THROUGHPUT SCREENING STUDIES OF INHIBITION OF HUMAN CARBONIC ANHYDRASE II AND BACTERIAL FLAGELLA ANTIMICROBIAL ACTIVITY by Albert A. Barrese III A Dissertation Submitted to the Faculty of The Graduate College in partial fulfillment of the requirements for the Degree of Doctor of Philosophy Department of Biological Sciences Advisor: Brian C. Tripp, Ph.D. Western Michigan University Kalamazoo, Michigan May 2010 UMI Number: 3410393 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. UMT Dissertation Publishing UMI 3410393 Copyright 2010 by ProQuest LLC.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Guidelines for the Management of Hyponatraemia in Hospitalised Patients
    Guidelines for the management of hyponatraemia in hospitalised patients Authors: V Mishra Aims: To provide guidelines for appropriate investigations and treatment of hyponatraemia in hospitalised patients. Normal range Mild Moderate hyponatraemia Severe hyponatraemia hyponatraemia 135-146 mmol/L 130-135 mmol/L 120-129 mmol/L <120 mmol/L Evaluation of hyponatraemia STEP 1: Rule out artefactual causes Is the patient on IV fluids? If so, could the sample have been taken “downstream” from the infusion site? Could the sample have been taken from the same line? STEP 2: Clinical history Check fluid balance to exclude fluid overload Is the patient diabetic? Hyperglycemia may cause dilutional hyponatraemia and increased urinary loss of sodium Correct serum sodium for hyperglycemia (rise in plasma glucose >5.5mmol/L) by using equation given in (Appendix 1) Consider medications (Table 1). In some cases, stopping the medication or changing to an alternative that does not cause hyponatraemia may be sufficient. Monitor sodium concentrations to assess the effects of this management. It may take several days for the sodium to normalise after withdrawing medications Review clinical history for relevant conditions (such as congestive cardiac failure, kidney disease, liver failure, lung pathology) Loss of weight /appetite: investigate for malignancy 1 Table 1: Drugs known to cause hyponatraemia Drug group Examples known to causecause hyponatraemia (other compounds may exist) TThiazidehiazide diuretics Bendroflumethiazide, Metolazone, Indapamide,
    [Show full text]
  • Diuretics in Clinical Practice. Part I: Mechanisms of Action, Pharmacological Effects and 1
    Review Diuretics in clinical practice. Part I: mechanisms of action, pharmacological effects and 1. Introduction clinical indications of diuretic 2. Principles of diuretic action and classification of diuretic compounds compounds † 3. Carbonic anhydrase inhibitors Pantelis A Sarafidis , Panagiotis I Georgianos & Anastasios N Lasaridis Aristotle University of Thessaloniki, AHEPA Hospital, Section of Nephrology and Hypertension, 4. Osmotic diuretics 1st Department of Medicine, Thessaloniki, St. Kiriakidi 1, 54636, Thessaloniki, Greece 5. Loop diuretics 6. Thiazides and thiazide-related Importance of the field: Diuretics are among the most important drugs of our diuretics therapeutic armamentarium and have been broadly used for > 50 years, 7. Potassium-retaining diuretics providing important help towards the treatment of several diseases. Although all diuretics act primarily by impairing sodium reabsorption in the renal 8. Conclusion tubules, they differ in their mechanism and site of action and, therefore, in 9. Expert opinion their specific pharmacological properties and clinical indications. Loop diure- tics are mainly used for oedematous disorders (i.e., cardiac failure, nephrotic syndrome) and for blood pressure and volume control in renal disease; thiazides and related agents are among the most prescribed drugs for hypertension treatment; aldosterone-blockers are traditionally used for primary or secondary aldosteronism; and other diuretic classes have more specific indications. Areas covered in this review: This article discusses the mechanisms of action, pharmacological effects and clinical indications of the various diuretic classes For personal use only. used in everyday clinical practice, with emphasis on recent knowledge sug- gesting beneficial effects of certain diuretics on clinical conditions distinct from the traditional indications of these drugs (i.e., heart protection for aldosterone blockers).
    [Show full text]
  • DIURETICS Diuretics Are Drugs That Promote the Output of Urine Excreted by the Kidneys
    DIURETICS Diuretics are drugs that promote the output of urine excreted by the Kidneys. The primary action of most diuretics is the direct inhibition of Na+ transport at one or more of the four major anatomical sites along the nephron, where Na+ reabsorption takes place. The increased excretion of water and electrolytes by the kidneys is dependent on three different processes viz., glomerular filtration, tubular reabsorption (active and passive) and tubular secretion. Diuretics are very effective in the treatment of Cardiac oedema, specifically the one related with congestive heart failure. They are employed extensively in various types of disorders, for example, nephritic syndrome, diabetes insipidus, nutritional oedema, cirrhosis of the liver, hypertension, oedema of pregnancy and also to lower intraocular and cerebrospinal fluid pressure. Therapeutic Uses of Diuretics i) Congestive Heart Failure: The choice of the diuretic would depend on the severity of the disorder. In an emergency like acute pulmonary oedema, intravenous Furosemide or Sodium ethacrynate may be given. In less severe cases. Hydrochlorothiazide or Chlorthalidone may be used. Potassium-sparing diuretics like Spironolactone or Triamterene may be added to thiazide therapy. ii) Essential hypertension: The thiazides usually sever as primary antihypertensive agents. They may be used as sole agents in patients with mild hypertension or combined with other antihypertensives in more severe cases. iii) Hepatic cirrhosis: Potassium-sparing diuretics like Spironolactone may be employed. If Spironolactone alone fails, then a thiazide diuretic can be added cautiously. Furosemide or Ethacrymnic acid may have to be used if the oedema is regractory, together with spironolactone to lessen potassium loss. Serum potassium levels should be monitored periodically.
    [Show full text]
  • Extracts from PRAC Recommendations on Signals Adopted at the 9-12 March 2020 PRAC
    6 April 20201 EMA/PRAC/111218/2020 Corr2,3 Pharmacovigilance Risk Assessment Committee (PRAC) New product information wording – Extracts from PRAC recommendations on signals Adopted at the 9-12 March 2020 PRAC The product information wording in this document is extracted from the document entitled ‘PRAC recommendations on signals’ which contains the whole text of the PRAC recommendations for product information update, as well as some general guidance on the handling of signals. It can be found here (in English only). New text to be added to the product information is underlined. Current text to be deleted is struck through. 1. Immune check point inhibitors: atezolizumab; cemiplimab; durvalumab – Tuberculosis (EPITT no 19464) IMFINZI (durvalumab) Summary of product characteristics 4.4. Special warnings and precautions for use Immune-mediated pneumonitis [..] Patients with sSuspected pneumonitis should be evaluated confirmed with radiographic imaging and other infectious and disease-related aetiologies excluded, and managed as recommended in section 4.2. LIBTAYO (cemiplimab) Summary of product characteristics 1 Expected publication date. The actual publication date can be checked on the webpage dedicated to PRAC recommendations on safety signals. 2 A footnote was deleted on 8 April 2020 for the signal on thiazide and thiazide-like diuretics (see page 3). 3 A minor edit was implemented in the product information of the signal on thiazide and thiazide-like diuretics on 5 June 2020 (see page 4). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]
  • Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research
    Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Garabedian, Laura Faden. 2013. Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research. Doctoral dissertation, Harvard University. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11156786 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research A dissertation presented by Laura Faden Garabedian to The Committee on Higher Degrees in Health Policy in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the subject of Health Policy Harvard University Cambridge, Massachusetts March 2013 © 2013 – Laura Faden Garabedian All rights reserved. Professor Stephen Soumerai Laura Faden Garabedian Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research Abstract This dissertation consists of two empirical papers and one methods paper. The first two papers use quasi-experimental methods to evaluate the impact of universal health insurance reform in Massachusetts (MA) and Thailand and the third paper evaluates the validity of a quasi- experimental method used in comparative effectiveness research (CER). My first paper uses interrupted time series with data from IMS Health to evaluate the impact of Thailand’s universal health insurance and physician payment reform on utilization of medicines for three non-communicable diseases: cancer, cardiovascular disease and diabetes.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pdf (329.48 K)
    Bull. Pharm. Sci., Assiut University, Vol. 29, Part 1, June 2006, pp. 33-58. SPECTROPHOTOMETRIC AND SPECTRO- FLUORIMETRIC DETERMINATION OF CERTAIN DIURETICS IN PURE FORMS AND IN THEIR PHARMACEUTICAL FORMULATIONS Michael E. El-Kommos1, Ahmad A. Ahmad2, Hesham Salem3* and Mahmoud A. Omar3 1Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Assiut University, Assiut, Egypt 2Department of Organic Chemistry, Faculty of Science, Minia University, Minia, Egypt 3Department of Analytical Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt ﺘﻬﺎ ( ، ، ، ، ، ، ، ) . ﻋﻠﻰ ٥٠٠ . ٧٢٠ . ٤- - ٧- ﻟﺼﻔﻴﺎ ٤٧٠ . ، ٥٣٥ . Three Simple and selective spectrophotometric and spectrofluorimetric methods were developed for the quantitative determination of certain diuretics (bendroflumethiazide, benzthiazide, chlorthalidone, clopamide, hydrochlorothiazide, hydroflumethiazide, indapamide and xipamide) in pure forms as well as in their pharmaceutical formulations through their hydroxamate formation and subsequent complexation with iron (method I), reaction with potassium ferricyanide (method II) and ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ Received in 11/9/2005 & Accepted in 12/3/2006 * Corresponding author E-mail address: [email protected] Michael E. El-Kommos, et al. reaction with 4-chloro-7-nitrobenzofurazan (method III). The conditions for different reactions were studied and optimized. The methods have been validated and successfully applied to the analysis of bulk drugs and their tablets with good recoveries ranging from 97.93 (±1.46) to 100.6 (±1.75) for method I, 98.49 (±1.43) to 99.86 (±0.87) for method II, and 98.98 (±1.11) to 99.90 (±0.86) for method III. No interference was observed from common pharmaceutical adjuvants. The results obtained compare well with those of reported methods. INTRODUCTION used for assay of chlorthalidone.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]